Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products, has initiated a clinical study evaluating the treatment of herpes labialis (cold sores) for its prescription topical cream candidate JW-100. The company believes this trial may be the first to analyze the efficacy of a combination CBD-aspartame product in the treatment of herpes labialis. JUPW’s topical cream, JW-100, features a dual mechanism of action and relief combined with CBD’s potential ability to induce apoptosis in epithelial cells infected with Kaposi sarcoma-associated herpes virus, with aspartame’s analgesic and anti-inflammatory properties. The study will include 40 patients enrolled through clinical sites in both Europe and Asia. Patients will have been diagnosed with recurrent herpes labialis infection (“HSV”) with initial infection at least a year previously. “We are rapidly advancing our clinical pipeline with our third indication,” said Jupiter CEO Brian John. “Herpes cold sores are common, with an estimated 48% of Americans aged 14-49 having had the HSV-1 virus. We believe JW-100 has the potential to treat and provide relief with fewer side effects than the treatments on the market today. This exploratory clinical trial is in line with a Phase I FDA study, and therefore we believe the resulting data will be a valuable addition to the Investigational New Drug (‘IND’) application we plan to file with the FDA for advanced stage trials in the U.S.”
To view the full press release, visit https://ibn.fm/LZlpX
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”)-based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced, skin-care therapeutics address indications including eczema, burns, herpes cold sores and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skin-care products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.